DBIA
AUTL

Dumont & Blake Investment Advisors’s Autolus Therapeutics AUTL Stock Holding History

Dumont & Blake Investment Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4K Sell
14,000
-1,000
-7% -$1.57K 0.01% 202
2026
Q1 		$20.7K Hold
15,000
– – 0.01% 200
2025
Q4 		$30K Hold
15,000
– – 0.01% 201
2025
Q3 		$24.4K Hold
15,000
– – 0.01% 204
2025
Q2 		$34.2K Hold
15,000
– – 0.01% 203
2025
Q1 		$23.3K Hold
15,000
– – 0.01% 202
2024
Q4 		$35.3K Buy
+15,000
New +$50.7K 0.01% 198

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dumont & Blake Investment Advisors's AUTL Position: Q2 2026 in Review

Dumont & Blake Investment Advisors reduced its Autolus Therapeutics (AUTL) stake by 6.7% in Q2 2026, selling an estimated $1.57K and leaving 14,000 shares worth $22.4K. The position accounts for 0.01% of the portfolio, ranked #202.

Dumont & Blake Investment Advisors first reported a position in AUTL in Q4 2024 and has held it in 7 quarters since. The position peaked at $35.3K in Q4 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Dumont & Blake Investment Advisors held 14,000 shares of Autolus Therapeutics worth $22.4K as of Q2 2026.
  • Dumont & Blake Investment Advisors sold 1,000 Autolus Therapeutics shares in Q2 2026, an estimated $1.57K.
  • Autolus Therapeutics made up 0.01% of Dumont & Blake Investment Advisors's portfolio in Q2 2026, its #202 holding.
  • Dumont & Blake Investment Advisors first reported a position in Autolus Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Dumont & Blake Investment Advisors's Autolus Therapeutics position peaked at $35.3K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Dumont & Blake Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.